HC Wainwright Lowers BioNTech (NASDAQ:BNTX) Price Target to $130.00

BioNTech (NASDAQ:BNTX) had its price target decreased by analysts at HC Wainwright from $140.00 to $130.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 45.38% from the stock’s previous close.

Several other research analysts have also recently issued reports on BNTX. Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a report on Wednesday, March 25th. Citigroup dropped their price target on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target on the stock. in a report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of BioNTech in a research note on Tuesday, March 17th. Finally, TD Cowen cut their target price on BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.07.

BioNTech Trading Up 0.6%

NASDAQ BNTX opened at $89.42 on Tuesday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $102.32 and its two-hundred day simple moving average is $101.33. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a market capitalization of $22.47 billion, a price-to-earnings ratio of -17.06 and a beta of 1.58.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Kennedy Capital Management LLC increased its position in shares of BioNTech by 0.8% during the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after acquiring an additional 127 shares in the last quarter. Larson Financial Group LLC lifted its position in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. Probity Advisors Inc. lifted its position in BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock valued at $247,000 after acquiring an additional 135 shares in the last quarter. Mackenzie Financial Corp boosted its stake in BioNTech by 4.0% during the 3rd quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock valued at $418,000 after purchasing an additional 165 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in BioNTech by 40.8% during the 3rd quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock valued at $77,000 after purchasing an additional 227 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.